NasdaqGS - Delayed Quote • USD
PTC Therapeutics, Inc. (PTCT)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 6:44 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 13 | 14 |
| Avg. Estimate | -1.52 | -1.58 | -5.78 | -4.87 |
| Low Estimate | -2.66 | -2.26 | -8.45 | -9.16 |
| High Estimate | -0.91 | -1.05 | -2.66 | -1.69 |
| Year Ago EPS | -2.66 | -1.76 | -8.37 | -5.78 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 11 | 13 | 13 |
| Avg. Estimate | 148.67M | 142.33M | 606.63M | 621.18M |
| Low Estimate | 134.44M | 113.9M | 469.7M | 350M |
| High Estimate | 169.37M | 154M | 680.24M | 806.36M |
| Year Ago Sales | 213.81M | 196.58M | 937.82M | 606.63M |
| Sales Growth (year/est) | -30.50% | -27.60% | -35.30% | 2.40% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -1.24 | -1.17 | 0.5 | -1.24 |
| EPS Actual | -2.66 | -1.76 | -2.06 | -1.2 |
| Difference | -1.42 | -0.59 | -2.56 | 0.04 |
| Surprise % | -114.50% | -50.40% | -512.00% | 3.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.52 | -1.58 | -5.78 | -4.87 |
| 7 Days Ago | -1.53 | -1.59 | -5.84 | -4.99 |
| 30 Days Ago | -1.54 | -1.6 | -5.88 | -4.98 |
| 60 Days Ago | -1.72 | -1.72 | -6.23 | -4.99 |
| 90 Days Ago | -1.71 | -1.71 | -6.02 | -4.81 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 2 | 2 |
| Up Last 30 Days | 3 | 3 | 4 | 4 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | PTCT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 42.90% | -- | -- | 6.50% |
| Next Qtr. | 10.20% | -- | -- | 12.00% |
| Current Year | 30.90% | -- | -- | 5.30% |
| Next Year | 15.70% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -9.51% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/12/2024 |
| Maintains | Jefferies: Buy to Buy | 3/20/2024 |
| Reiterates | RBC Capital: Sector Perform to Sector Perform | 3/8/2024 |
| Maintains | RBC Capital: Sector Perform to Sector Perform | 3/1/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/1/2024 |
| Maintains | TD Cowen: Market Perform to Market Perform | 3/1/2024 |
Related Tickers
CGON CG Oncology, Inc.
41.00
+13.26%
RARE Ultragenyx Pharmaceutical Inc.
44.24
+0.89%
APGE Apogee Therapeutics, Inc.
47.13
+2.77%
INSM Insmed Incorporated
24.80
-0.48%
BPMC Blueprint Medicines Corporation
93.00
+2.50%
CGEM Cullinan Therapeutics, Inc.
25.30
+31.43%
AGIO Agios Pharmaceuticals, Inc.
31.49
-0.57%
SAGE Sage Therapeutics, Inc.
13.69
+0.81%
MRUS Merus N.V.
45.04
+0.24%
APLS Apellis Pharmaceuticals, Inc.
49.86
+4.03%